Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ajith Purush

Internal Medicine Prescott, AZ Medical Doctor

NPI 1699761437 CMS profile 31200

722 N Montezuma St, Prescott, AZ 86301

Open in the dashboard

General payments

$5,355

283 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ajith Purush of Prescott, AZ is reported in the CMS Open Payments database as having received $5,355 across 283 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $668 29
2024 General $817 43
2023 General $886 50
2022 General $846 43
2021 General $415 25
2020 General $753 33
2019 General $971 60

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ajith Purush
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Ajith Purush were reported at $668. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Ajith Purush Internal Medicine median Middle half National median
2019 $971 $159 $48–$570 $163
2020 $753 $119 $33–$402 $114
2021 $415 $135 $37–$521 $132
2022 $846 $141 $42–$496 $149
2023 $886 $149 $45–$519 $160
2024 $817 $154 $47–$537 $164
2025 $668 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $799 49 payments
  2. Lilly USA, LLC $772 41 payments
  3. GlaxoSmithKline, LLC. $748 45 payments
  4. Abbott Laboratories $593 22 payments
  5. Amgen Inc. $424 24 payments
  6. Sumitomo Pharma America, Inc. $282 13 payments
  7. Janssen Pharmaceuticals, Inc $253 21 payments
  8. Watermark Medical, Inc. $225 1 payment
  9. Bayer HealthCare Pharmaceuticals Inc. $149 7 payments
  10. Merck Sharp & Dohme Corporation $116 6 payments
  11. Other $994 54 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,336 281 payments
  2. Education $19 2 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $653 40 payments
  2. JARDIANCE $484 24 payments
  3. FARXIGA $478 30 payments
  4. BREZTRI $349 18 payments
  5. EVENITY $348 19 payments
  6. GEMTESA $335 16 payments
  7. Prolia $290 16 payments
  8. XARELTO $235 19 payments
  9. MOUNJARO $208 11 payments
  10. Confirm Rx $196 7 payments
  11. Other $3,080 172 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 199 drugs

Part D claims

16,694

Median for General Practice: 1,105

Drug cost

$1,164,052

Median for General Practice: $48,734

Branded share of claims

16.8%

Median for General Practice: 17.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 143 $160,852
Farxiga Dapagliflozin Propanediol Brand 78 $97,645
Ozempic Semaglutide Brand 59 $86,782
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 66 $66,412
Januvia Sitagliptin Phosphate Brand 59 $64,230
Jardiance Empagliflozin Brand 49 $64,016
Xarelto Rivaroxaban Brand 34 $53,157
Creon Lipase/Protease/Amylase Brand 27 $49,748
Gemtesa Vibegron Brand 56 $45,056
Mounjaro Tirzepatide Brand 27 $31,338

The 10 drugs with the highest cost, of 199 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,210 Part D prescribers listed as General Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 76 billing codes

Paid by Medicare

$723,285

Of which drugs: $491

Medicare patients

1,336

Average age 76

Services billed

14,268

670 women, 666 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Ischemic heart disease 28%
Chronic kidney disease 28%
Atrial fibrillation 20%
Osteoporosis 18%
Diabetes 16%
Cancer 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Influenza vaccine, trivalent, 0.5 ml dosage 90658 Office 21 21 $450
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 14 42 $8
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 17 24 $7

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $117
$117 78 —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $99
$99 66 —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $82
$82 15 —
MOUNJARO
  • Lilly USA, LLC $77
$77 27 —
ZEPBOUND
  • Lilly USA, LLC $70
$70 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

283 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record